Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.43 |
| ▸ | POLB | P06746 | 4/20 | 0.43 |
| ▸ | RAB9A | P51151 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | NQO2 | P16083 | 1/20 | 0.43 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.40 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA3 | P07451 | 1/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL940594 | 0.87 | ALDH1A1 (0.44) | ALDH1A1KDM4EPOLBRAB9AMEN1 | |
| SCHEMBL11786390 | 0.81 | KMT2A (0.45) | ALDH1A1KDM4ERAB9AMEN1KMT2A | |
| SCHEMBL939151 | 0.75 | KDM4E (0.43) | ALDH1A1KDM4ERAB9AMEN1KMT2A | |
| SCHEMBL207905 | 0.71 | PIK3CG (0.44) | ALDH1A1KDM4EPOLBMEN1KMT2A | |
| SCHEMBL4150810 | 0.71 | KDM4E (0.42) | ALDH1A1KDM4EPOLBRAB9AMEN1 | |
| SCHEMBL207175 | 0.71 | BACE1 (0.34) | ALDH1A1MEN1KMT2ACYP1A2CYP2C19 | |
| SCHEMBL11784333 | 0.70 | SCN10A (0.36) | ALDH1A1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL5708068 | 0.69 | NPC1 (0.35) | ALDH1A1KDM4EPOLBRAB9AMEN1 | |
| SCHEMBL926856 | 0.68 | KDM4E (0.48) | ALDH1A1KDM4EPOLBRAB9AMEN1 | |
| SCHEMBL938963 | 0.67 | NPC1 (0.42) | ALDH1A1KDM4EPOLBRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158025-A1 | GALACTOKINASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH | 2023-05-25 | — | — | US | claimed |
| WO-2021216812-A1 | GALACTOKINASE INHIBITORS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2021-10-28 | — | — | WO | claimed |
| US-20230158025-A1 | GALACTOKINASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH | 2023-05-25 | — | — | US | disclosed |
| WO-2021216812-A1 | GALACTOKINASE INHIBITORS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2021-10-28 | — | — | WO | disclosed |
| EP-2415763-B1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING GLAUCOMA | UBE INDUSTRIES (JP) | 2016-01-27 | — | — | EP | disclosed |
| US-20140113907-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2014-04-24 | — | — | US | disclosed |
| US-8648097-B2 | Pyridylaminoacetic acid compound | UBE INDUSTRIES, LTD. (JP) | 2014-02-11 | — | — | US | disclosed |
| US-20120190852-A1 | MEDICAL COMPOSITION FOR TREATMENT OR PROPHYLAXIS OF GLAUCOMA | UBE INDUSTRIES, LTD. (JP) | 2012-07-26 | — | — | US | disclosed |
| EP-2415763-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING GLAUCOMA | Ube Industries, Ltd. (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20110054172-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | UBE CORPORATION (JP) | 2011-03-03 | — | — | US | disclosed |
| US-7875606-B2 | Herbicides; selectivity between crops and weeds | IHARA CHEMICAL INDUSTRY CO., LTD. (JP) | 2011-01-25 | — | — | US | disclosed |
| US-7238689-B2 | Isoxazoline derivative and herbicide comprising the same as active ingredient | IHARA CHEMICAL INDUSTRY CO., LTD. (JP) | 2007-07-03 | — | — | US | disclosed |
| US-7091360-B2 | Process for preparing heteroaryl and unsaturated heterocycloalkylmagnesium reagents and uses thereof | AVENTIS PHARMA S.A. (US) | 2006-08-15 | — | — | US | disclosed |
| US-20060135781-A1 | Process for preparing heteroaryl and unsaturated heterocycloalkylmagnesium reagents and uses thereof | AVENTIS PHARMACEUTICALS, INC. | 2006-06-22 | — | — | US | disclosed |
| EP-1495007-A4 | PROCESS FOR PREPARING HETEROARYL AND UNSATURATED HETEROCYCLOALKYLMAGNESIUM REAGENTS AND USES | AXYS PHARM INC (US) | 2006-05-03 | — | — | EP | disclosed |
| EP-1495007-A1 | PROCESS FOR PREPARING HETEROARYL AND UNSATURATED HETEROCYCLOALKYLMAGNESIUM REAGENTS AND USES | AXYS PHARMACEUTICALS, INC. (US) | 2005-01-12 | — | — | EP | disclosed |
| EP-1405853-A1 | ISOXAZOLINE DERIVATIVES AND HERBICIDES | KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) | 2004-04-07 | — | — | EP | disclosed |
| US-20040019218-A1 | Process for preparing heteroaryl and unsaturated heterocycloalkylmagnesium reagents and uses thereof | AXYS PHARMACEUTICALS, INC. | 2004-01-29 | — | — | US | disclosed |
| WO-2003087068-A1 | PROCESS FOR PREPARING HETEROARYL AND UNSATURATED HETEROCYCLOALKYLMAGNESIUM REAGENTS AND USES | AXYS PHARMACEUTICALS, INC. (US) | 2003-10-23 | — | — | WO | disclosed |
| EP-0878194-A1 | REMEDIES OR PREVENTIVES FOR AIDS | SANKYO COMPANY LIMITED (JP) | 1998-11-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019218-A1 | Process for preparing heteroaryl and unsaturated heterocycloalkylmagnesium reagents and uses thereof | SPINT2, CTSV, CTSZ | ALDH1A1 2466/4885KDM4E 4252/4885POLB 4166/4885 |
| US-20230158025-A1 | GALACTOKINASE INHIBITORS | GALK1, GCK, GCKR | ALDH1A1 3139/4885KDM4E 2218/4885POLB 3401/4885 |
| US-20140113907-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | PTGER2, PTGER1, PTGDR2 | ALDH1A1 204/4885KDM4E 2779/4885POLB 3280/4885 |
| US-20060135781-A1 | Process for preparing heteroaryl and unsaturated heterocycloalkylmagnesium reagents and uses thereof | SPINT2, CTSV, CTSZ | ALDH1A1 2466/4885KDM4E 4252/4885POLB 4166/4885 |
| US-20110054172-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | PTGER2, PTGER1, PTGDR2 | ALDH1A1 256/4885KDM4E 2804/4885POLB 3560/4885 |
| US-20120190852-A1 | MEDICAL COMPOSITION FOR TREATMENT OR PROPHYLAXIS OF GLAUCOMA | F12, C1S, AKR1C3 | ALDH1A1 377/4885KDM4E 3706/4885POLB 2959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.